Dawson D L
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA.
Am J Cardiol. 2001 Jun 28;87(12A):19D-27D. doi: 10.1016/s0002-9149(01)01673-3.
Many patients with peripheral arterial disease (PAD) have intermittent claudication or problems with ambulation and mobility. Exercise and smoking cessation are primary therapies for claudication, but drug treatment may provide additional benefit. The data supporting use of pentoxifylline for claudication are weak, and pentoxifylline is not generally accepted as efficacious. Cilostazol is a new drug for the treatment of claudication. It appears to modestly benefit walking ability and it has other potentially useful effects, including inhibition of platelet aggregation and beneficial effects on serum lipids. In a randomized, prospective, double-blind trial examining walking ability in patients with PAD with moderate-to-severe claudication, cilostazol was superior to both placebo and pentoxifylline.
许多外周动脉疾病（PAD）患者存在间歇性跛行或行走及活动方面的问题。运动和戒烟是治疗跛行的主要疗法，但药物治疗可能会带来额外益处。支持使用己酮可可碱治疗跛行的数据并不充分，且己酮可可碱一般未被认为有效。西洛他唑是一种用于治疗跛行的新药。它似乎能适度改善行走能力，还有其他潜在有益作用，包括抑制血小板聚集以及对血脂的有益影响。在一项针对中重度跛行的PAD患者行走能力的随机、前瞻性、双盲试验中，西洛他唑优于安慰剂和己酮可可碱。
